Opinion No 91 - Access to Raw Data Generated by Whole Genome or Whole Exome Sequencing

Opinion No 91 of 22 June 2026 concerning access to raw data generated by whole genome sequencing or whole exome sequencing (WGS or WES)

In this opinion, the Committee examines the ethical, legal and societal issues related to patients’ access to raw data generated through whole genome sequencing (WGS) and whole exome sequencing (WES). The Committee recognises the importance of the right of individuals to access their own data, while emphasising that such raw genomic data cannot be equated with clinical information that is directly communicable or immediately understandable. Indeed, their meaning depends on a process of professional analysis, interpretation and contextualisation. The Committee also draws attention to the inherently familial and collective nature of genetic data, which may have implications for biological relatives. It therefore advocates a responsible framework for access to such data, balancing patient autonomy, the protection of the rights and interests of relatives, the quality of medical interpretation and the confidentiality of genetic information.

Opinion by letter No  21 - The reimbursement of additional IVF cycles in the context of PGT‑M

Opinion by letter No 21 of 12 March 2026 on the reimbursement of additional IVF cycles in the context of PGT‑M 

This opinion by letter addresses the question of whether it is appropriate to reimburse additional in vitro fertilisation (IVF) cycles when couples who are carriers of a hereditary genetic disorder use pre‑implantation genetic testing (PGT‑M) in order to avoid transmitting this condition to their future child. In Belgium, reimbursement is currently limited to six IVF cycles, regardless of the reason for the treatment. The Committee examines whether this rule leads, in the context of PGT‑M, to an equitable situation, given that certain embryos cannot be transferred because of an identified genetic risk. The opinion analyses this issue in the light of available scientific data and ethical considerations, in particular with regard to equality between patients, equity of outcomes, social justice and the responsible use of healthcare resources. It also highlights the possible alternatives that these couples may be confronted with. The Committee does not take a decision on reimbursement, but sets out the ethical issues that are relevant for political decision‑making bodies.

Opinion No 38 -  Genetic testing to determine descent after death

Opinion No 38 of November 13th, 2006 on genetic testing to determine descent after death.

Opinion No 37 -  DNA testing in matters of determining parentage

Opinion No 37 of November 13, 2006, concerning the use of DNA testing in matters of determining parentage.

Opinion No 32 -  Free availability of genetic tests

Opinion No 32 of 5 July 2004 on the free availability of genetic tests.

Opinion No 20 - Predictive genetic testing and HIV testing in the context of employment relations

Opinion No 20 of November 18, 2002, by the Advisory Committee on Bioethics of Belgium concerns predictive genetic testing and HIV testing in the context of employment relations.